Free Trial
→ How one AI fund pays investors every Thursday (From Investors Alley) (Ad)tc pixel Free TTOO Stock Alerts

T2 Biosystems (TTOO) Competitors

T2 Biosystems logo
$0.0008 0.00 (0.00%)
As of 10/12/2026 10:12 AM Eastern
Compare

TTOO vs. SDCCQ, GMVDF, VRAYQ, AFIB, and UTRS

Should you buy T2 Biosystems stock or one of its competitors? T2 Biosystems's main competitors and comparable companies include SmileDirectClub (SDCCQ), G Medical Innovations (GMVDF), ViewRay (VRAYQ), Acutus Medical (AFIB), and Minerva Surgical (UTRS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does T2 Biosystems compare to SmileDirectClub?

T2 Biosystems (NASDAQ:TTOO) and SmileDirectClub (NASDAQ:SDCCQ) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

In the previous week, T2 Biosystems' average media sentiment score of 0.00 equaled SmileDirectClub'saverage media sentiment score.

Company Overall Sentiment
T2 Biosystems Neutral
SmileDirectClub Neutral

23.2% of T2 Biosystems shares are owned by institutional investors. Comparatively, 0.1% of SmileDirectClub shares are owned by institutional investors. 0.0% of T2 Biosystems shares are owned by company insiders. Comparatively, 64.7% of SmileDirectClub shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

T2 Biosystems has higher earnings, but lower revenue than SmileDirectClub. T2 Biosystems is trading at a lower price-to-earnings ratio than SmileDirectClub, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
T2 Biosystems$7.68M0.00-$50.08M-$3.89N/A
SmileDirectClub$470.74M0.00-$86.40M-$0.13N/A

T2 Biosystems has a beta of 8.13, suggesting that its share price is 713% more volatile than the broader market. Comparatively, SmileDirectClub has a beta of 1.35, suggesting that its share price is 35% more volatile than the broader market.

SmileDirectClub has a net margin of 0.00% compared to T2 Biosystems' net margin of -563.16%.

Company Net Margins Return on Equity Return on Assets
T2 Biosystems-563.16% N/A -174.06%
SmileDirectClub N/A N/A N/A

Summary

SmileDirectClub beats T2 Biosystems on 5 of the 9 factors compared between the two stocks.

How does T2 Biosystems compare to G Medical Innovations?

T2 Biosystems (NASDAQ:TTOO) and G Medical Innovations (NASDAQ:GMVDF) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk, earnings and dividends.

23.2% of T2 Biosystems shares are owned by institutional investors. Comparatively, 6.0% of G Medical Innovations shares are owned by institutional investors. 0.0% of T2 Biosystems shares are owned by company insiders. Comparatively, 37.1% of G Medical Innovations shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, T2 Biosystems' average media sentiment score of 0.00 equaled G Medical Innovations'average media sentiment score.

Company Overall Sentiment
T2 Biosystems Neutral
G Medical Innovations Neutral

G Medical Innovations has a net margin of 0.00% compared to T2 Biosystems' net margin of -563.16%.

Company Net Margins Return on Equity Return on Assets
T2 Biosystems-563.16% N/A -174.06%
G Medical Innovations N/A N/A N/A

T2 Biosystems has a beta of 8.13, suggesting that its stock price is 713% more volatile than the broader market. Comparatively, G Medical Innovations has a beta of 28.66, suggesting that its stock price is 2,766% more volatile than the broader market.

G Medical Innovations has lower revenue, but higher earnings than T2 Biosystems.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
T2 Biosystems$7.68M0.00-$50.08M-$3.89N/A
G Medical Innovations$4.42M0.00-$24.63MN/AN/A

Summary

G Medical Innovations beats T2 Biosystems on 5 of the 7 factors compared between the two stocks.

How does T2 Biosystems compare to ViewRay?

ViewRay (NASDAQ:VRAYQ) and T2 Biosystems (NASDAQ:TTOO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

ViewRay has a net margin of 0.00% compared to T2 Biosystems' net margin of -563.16%.

Company Net Margins Return on Equity Return on Assets
ViewRayN/A N/A N/A
T2 Biosystems -563.16%N/A -174.06%

ViewRay has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market. Comparatively, T2 Biosystems has a beta of 8.13, meaning that its share price is 713% more volatile than the broader market.

15.5% of ViewRay shares are owned by institutional investors. Comparatively, 23.2% of T2 Biosystems shares are owned by institutional investors. 2.5% of ViewRay shares are owned by insiders. Comparatively, 0.0% of T2 Biosystems shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

T2 Biosystems has lower revenue, but higher earnings than ViewRay.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ViewRay$102.21M0.00-$107.33MN/AN/A
T2 Biosystems$7.68M0.00-$50.08M-$3.89N/A

In the previous week, ViewRay's average media sentiment score of 0.00 equaled T2 Biosystems'average media sentiment score.

Company Overall Sentiment
ViewRay Neutral
T2 Biosystems Neutral

Summary

ViewRay and T2 Biosystems tied by winning 4 of the 8 factors compared between the two stocks.

How does T2 Biosystems compare to Acutus Medical?

T2 Biosystems (NASDAQ:TTOO) and Acutus Medical (NASDAQ:AFIB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.

Acutus Medical has a net margin of -272.74% compared to T2 Biosystems' net margin of -563.16%. T2 Biosystems' return on equity of 0.00% beat Acutus Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
T2 Biosystems-563.16% N/A -174.06%
Acutus Medical -272.74%-311.64%-11.57%

T2 Biosystems has higher revenue and earnings than Acutus Medical. Acutus Medical is trading at a lower price-to-earnings ratio than T2 Biosystems, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
T2 Biosystems$7.68M0.00-$50.08M-$3.89N/A
Acutus Medical$7.16M0.00-$81.66M-$0.11N/A

T2 Biosystems has a beta of 8.13, suggesting that its share price is 713% more volatile than the broader market. Comparatively, Acutus Medical has a beta of 5.71, suggesting that its share price is 471% more volatile than the broader market.

In the previous week, T2 Biosystems' average media sentiment score of 0.00 equaled Acutus Medical'saverage media sentiment score.

Company Overall Sentiment
T2 Biosystems Neutral
Acutus Medical Neutral

23.2% of T2 Biosystems shares are owned by institutional investors. Comparatively, 56.9% of Acutus Medical shares are owned by institutional investors. 0.0% of T2 Biosystems shares are owned by company insiders. Comparatively, 5.2% of Acutus Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

T2 Biosystems beats Acutus Medical on 6 of the 11 factors compared between the two stocks.

How does T2 Biosystems compare to Minerva Surgical?

Minerva Surgical (NASDAQ:UTRS) and T2 Biosystems (NASDAQ:TTOO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Minerva Surgical has a net margin of 0.00% compared to T2 Biosystems' net margin of -563.16%.

Company Net Margins Return on Equity Return on Assets
Minerva SurgicalN/A N/A N/A
T2 Biosystems -563.16%N/A -174.06%

Minerva Surgical has a beta of 2.37, indicating that its stock price is 137% more volatile than the broader market. Comparatively, T2 Biosystems has a beta of 8.13, indicating that its stock price is 713% more volatile than the broader market.

23.2% of T2 Biosystems shares are owned by institutional investors. 8.5% of Minerva Surgical shares are owned by insiders. Comparatively, 0.0% of T2 Biosystems shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Minerva Surgical has higher revenue and earnings than T2 Biosystems. T2 Biosystems is trading at a lower price-to-earnings ratio than Minerva Surgical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Minerva Surgical$51.69M0.00-$34.11M-$1.81N/A
T2 Biosystems$7.68M0.00-$50.08M-$3.89N/A

In the previous week, Minerva Surgical's average media sentiment score of 0.00 equaled T2 Biosystems'average media sentiment score.

Company Overall Sentiment
Minerva Surgical Neutral
T2 Biosystems Neutral

Summary

Minerva Surgical beats T2 Biosystems on 7 of the 9 factors compared between the two stocks.

Get T2 Biosystems News Delivered to You Automatically

Sign up to receive the latest news and ratings for TTOO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TTOO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TTOO vs. The Competition

Export
MetricT2 BiosystemsHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$17K$5.58B$7.26B$13.21B
Dividend YieldN/A1.75%2.52%22.89%
P/E Ratio0.0020.86204.9519.81
Price / Sales0.0067.21562.0081.34
Price / CashN/A32.2577.1653.04
Price / Book0.005.8610.756.03
Net Income-$50.08M$146.14M$3.50B$380.34M
7 Day PerformanceN/A-0.98%-2.90%-2.34%
1 Month PerformanceN/A-3.62%-7.37%-5.31%
1 Year PerformanceN/A1.42%2.97%-2.94%

T2 Biosystems Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TTOO
T2 Biosystems
N/A$0.00
flat		N/A-88.6%$17K$7.68MN/A113
SDCCQ
SmileDirectClub
N/AN/AN/AN/A$40K$470.74MN/A2,700
GMVDF
G Medical Innovations
N/AN/AN/AN/A$26K$4.42MN/A84
VRAYQ
ViewRay
N/AN/AN/AN/A$16K$102.21MN/A295
AFIB
Acutus Medical
N/AN/AN/A-80.0%$3K$7.16MN/A85

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:TTOO) was last updated on 10/14/2026 by MarketBeat.com Staff.
From Our Partners
The AI Infrastructure Play Kevin O'Leary Is Backing
Kevin O'Leary became a strategic investor in a NASDAQ-listed AI infrastructure company, calling it essentially...
The Tomorrow Investor | Sponsoredtc pixel
Wall Street legend reveals his top AI stock before Oct. 20
Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock...
Chaikin Analytics | Sponsoredtc pixel
Elon Musk’s One Stock Retirement Plan
Jeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...
Brownstone Research | Sponsoredtc pixel
Fox News: Wall Street Can Seize Your Retirement
Fox News reported that under current law, legal title to most stocks and bonds sits with a central institution...
Monetary Gold | Sponsoredtc pixel
Trump's about to unleash his Midterm Weapon
Trump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...
Monument Traders Alliance | Sponsoredtc pixel
Federal Reserve Reveals Disturbing New Plan To Control Your Money
Docket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on p...
Weiss Ratings | Sponsoredtc pixel
I'm giving you a space stock today. Free.
On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any...
Behind the Markets | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel